Target Identification and Prioritization
Identify tumor dependency genes and novel therapeutic targets through genome-wide CRISPR screening, synthetic lethality screening, and non-coding region functional analysis.
As a preclinical CRO specializing in oncology, Alfa Cytology provides comprehensive cancer gene research and validation services designed to accelerate your drug discovery pipeline, from target identification and functional validation through IND-enabling studies. Leveraging advanced gene editing platforms, customizable vector systems, high-titer virus packaging, and integrated in vitro/in vivo functional study platforms, our senior scientists deliver high-quality, reproducible solutions tailored to your specific research needs.
Cancer gene research and validation represent a core component of modern cancer biology, with their necessity rooted in the molecular complexity of tumors, cancer initiation, progression, metastasis, and drug resistance are not determined by a single gene, but rather arise from the combined effects of multiple genetic alterations and dysregulated signaling networks. Only through systematic gene research and functional validation can genuine driver genes be distinguished from passenger mutations that confer no growth advantage, thereby preventing research resources from being directed toward targets lacking biological rationale. By precisely modulating gene expression and function, researchers can dissect downstream signaling pathways, identify therapeutically actionable vulnerabilities, and provide a reliable molecular basis for subsequent mechanistic studies and drug development. Efficient gene research and validation depend on an integrated research strategy: constructing isogenic cell models through precise genome editing, achieving controllable gene expression or silencing via customized vectors, enabling efficient delivery through high-titer viral vectors, and evaluating phenotypic outcomes in vitro and in vivo through comprehensive functional studies. This end-to-end approach not only ensures that every experimental data point is traceable and reproducible, but also enables seamless translation from mechanistic exploration to preclinical validation, substantially reducing the risk of target validation failure and laying a solid foundation for subsequent translational research.
Fig. 1 Schematic representation of gRNA library construction and virus production. (Qin M, et al.; 2024)
At Alfa Cytology, our cancer gene research and validation services span the entire workflow—from precise genome modification and customizable vector construction to high-titer virus packaging and systematic functional evaluation. Each service is supported by rigorous quality control and comprehensive validation to ensure reproducible, publication-ready results. By integrating advanced gene editing platforms, flexible delivery systems, and multi-level validation frameworks, we empower researchers to dissect gene function, model disease mechanisms, and validate therapeutic targets with confidence.
Whether you are conducting basic mechanistic studies, building disease-relevant models, or advancing candidate therapeutics toward the clinic, our end-to-end solutions are designed to meet diverse research objectives and accelerate every stage of your drug discovery pipeline. Our services include, but are not limited to:
Gene editing is a core technology for elucidating gene function, constructing disease models, and validating therapeutic targets. Alfa Cytology provides comprehensive gene editing services built upon a CRISPR/Cas9 core platform and integrated with complementary technologies including base editing, prime editing, and CRISPRi/a, accommodating the full spectrum of research needs, from editing precision assessment and custom library construction to the generation of stable knockout, knock-in, and point mutation models in both cell lines and mice.
High-quality vector systems are essential for generating isogenic cancer cell lines, establishing reporter-based screening platforms, producing recombinant proteins, and constructing animal models. Alfa Cytology offers a comprehensive portfolio of vector construction services, encompassing gene overexpression, RNA interference, CRISPR/Cas editing, promoter reporter constructs, protein-protein interaction tools, custom gene synthesis, high-throughput site-directed mutagenesis, and full-length RACE cloning.
Efficient gene delivery is a critical step in both in vitro gene modulation and in vivo gene therapy research. We provides comprehensive virus packaging services covering lentivirus, adenovirus, and adeno-associated virus (AAV) systems. Each viral batch is subjected to rigorous quality control, including titer determination, purity assessment, and functional validation, ensuring reliability and reproducibility in downstream applications ranging from in vitro gene modulation to in vivo gene delivery.
Gene function studies serve as a critical bridge connecting genotype to phenotype and elucidating tumor biological behavior. Alfa Cytology provides comprehensive gene function study services spanning both in vitro and in vivo platforms to systematically evaluate the impact of genes on tumor biological behaviors. Leveraging advanced gene modulation tools and a diverse array of phenotypic detection platforms, we deliver high-quality, reproducible functional study solutions supporting target discovery, validation, and preclinical drug development.
Our cancer gene research and validation services span every stage of drug discovery, from target discovery to preclinical evaluation, providing reliable data support for each research decision.
Target Discovery
Target Validation
Mechanism of Action (MoA) Studies
Preclinical Evaluation
Our integrated workflow ensures seamless progression from target discovery to preclinical validation, with each module designed to interface efficiently with the next.
Target Identification and Prioritization
Identify tumor dependency genes and novel therapeutic targets through genome-wide CRISPR screening, synthetic lethality screening, and non-coding region functional analysis.
Gene Modulation Tool Construction
Design and construct gene editing components, overexpression/RNAi vectors, and virus packaging systems based on your specific research objectives.
Model Generation and Validation
Generate stable knockout, knockin, point mutation, and overexpression models in both cell lines and mouse models, with comprehensive validation at the genomic, transcriptomic, and protein levels.
In Vitro Functional Characterization
Systematically evaluate phenotypes including proliferation, apoptosis, migration, invasion, drug resistance, and metabolism using CCK-8, flow cytometry, Transwell assays, 3D culture, and organoid models.
In Vivo Functional Validation
Assess gene function using CDX, PDX, and GEMM models, combined with in vivo imaging, tumor growth monitoring, histopathological analysis, and molecular biomarker detection.
Data Integration and Reporting
Cross-validate in vitro and in vivo findings, comprehensively analyze data, and deliver publication-ready reports to support target prioritization and drug discovery decision-making.
Leveraging our oncology expertise, the gene research and validation platform supports a broad spectrum of solid tumors and hematological malignancies, backed by extensive experience in the discovery and functional validation of novel therapeutic targets across diverse indications.
Our gene research and validation platform supports the development and validation of multiple therapeutic modalities. Thanks to core technologies such as gene editing, vector construction, virus packaging, and functional studies, we provide tailored research and validation solutions for the following therapeutic modalities:
Alfa Cytology integrates cutting-edge gene research technologies with rigorous project management and scientific excellence, delivering end-to-end support for oncology research, from target discovery to preclinical validation. Whether you are exploring novel gene functions, constructing disease models, or advancing therapeutic candidates toward the clinic, we deliver high-quality, reproducible research data to accelerate your drug discovery process. Contact us to discuss your project requirements and learn how Alfa Cytology can support your research through end-to-end cancer gene research and validation services.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.